- Conditions
- Small Cell Lung Cancer
- Interventions
- Ifinatamab deruxtecan, Topotecan, Amrubicin, Lurbinectedin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 30
- States / cities
- Springdale, Arkansas • Fullerton, California • Los Angeles, California + 24 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 328
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Lung Cancer
- Interventions
- cisplatin, etoposide, topotecan hydrochloride
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2002
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- HIV Infections, Leukoencephalopathy, Progressive Multifocal
- Interventions
- Topotecan
- Drug
- Lead sponsor
- SmithKline Beecham
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Francisco, California • Miami, Florida + 2 more
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Bevacizumab, Gemcitabine Hydrochloride, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
- Biological · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms, Small Cell Lung Carcinoma, Uterine Cervical Neoplasms, Carcinoma, Neuroendocrine, Extrapulmonary Small Cell Cancer
- Interventions
- Topotecan, VX-970 (M6620)
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
- Interventions
- 75 approved agents, COXEN
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- topotecan hydrochloride
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 78
- States / cities
- Hartford, Connecticut • New Britain, Connecticut • Lewes, Delaware + 60 more
- Conditions
- Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, External Beam Radiation Therapy, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Intensity-Modulated Radiation Therapy, Iobenguane I-131, Isotretinoin, Laboratory Biomarker Analysis, Melphalan, Pharmacological Study, Questionnaire Administration, Therapeutic Conventional Surgery, Topotecan Hydrochloride, Vincristine Sulfate
- Radiation · Procedure · Drug + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2025
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more
- Conditions
- Recurrent Small Cell Lung Carcinoma
- Interventions
- Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Topotecan Hydrochloride
- Drug · Other
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Solid Tumors, Lymphomas
- Interventions
- ABT-888, Topotecan
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lymphoma
- Interventions
- doxorubicin hydrochloride, topotecan hydrochloride
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 75
- States / cities
- Anniston, Alabama • La Jolla, California • San Diego, California + 54 more
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage III Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
- Interventions
- Filgrastim, Laboratory Biomarker Analysis, Pegfilgrastim, Topotecan Hydrochloride, Veliparib
- Biological · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 78
- States / cities
- Orange, California • Aurora, Colorado • Hartford, Connecticut + 56 more
- Conditions
- Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- topotecan hydrochloride
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Up to 120 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more
- Conditions
- Ovarian Neoplasms
- Interventions
- TLK286 HCl for injection, topotecan hydrochloride for injection, doxorubicin HCl liposome injection
- Drug
- Lead sponsor
- Telik
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 234
- States / cities
- Little Rock, Arkansas • Baldwin Park, California • Burbank, California + 146 more
- Conditions
- Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer
- Interventions
- M7824, Topotecan, Temozolomide, EKG, CT scan, PET scan, Acetaminophen, Antihistamines, Diphenhydramine, Dexamethasone, Epinephrine
- Drug · Diagnostic Test
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Talazoparib, Topotecan, Gemcitabine
- Drug
- Lead sponsor
- Norman J. Lacayo
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 6 more
- Conditions
- Lung Cancer
- Interventions
- paclitaxel, topotecan hydrochloride, radiation therapy
- Drug · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2006
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Cediranib, Cediranib Maleate, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Questionnaire Administration, Topotecan, Topotecan Hydrochloride
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 370
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 285 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- AT-101, topotecan
- Drug
- Lead sponsor
- Ascenta Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • Loma Linda, California + 14 more
- Conditions
- Retinoblastoma
- Interventions
- Intra-arterial Chemotherapy
- Procedure
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 1 Month and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
- Interventions
- Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Iowa City, Iowa • Cleveland, Ohio + 2 more
- Conditions
- Gynecologic Tumors
- Interventions
- Oral Topotecan, Pazopanib
- Drug
- Lead sponsor
- Vector Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Carcinoma, Small Cell
- Interventions
- Topotecan, carboplatin
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 16
- States / cities
- Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 13 more
- Conditions
- Small Cell Lung Carcinoma (SCLC)
- Interventions
- BI 764532, Topotecan, Single agent chemotherapy
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Jacksonville, Florida • Miami, Florida + 1 more